SCHEDULE: Deep Track Capital Discloses 5.33% Stake in Enanta Pharma
Beneficial Ownership Report
Deep Track Capital, LP and its affiliates have reported a 5.33% beneficial ownership stake in Enanta Pharmaceuticals Inc., totaling 1,484,513 shares.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 1,484,513 shares of Enanta Pharmaceuticals Inc. Common Stock.
- This ownership represents 5.33% of the issuer's outstanding Common Stock, calculated based on 27,877,923 shares outstanding as of October 1, 2025.
- The reporting persons share both voting and dispositive power over all 1,484,513 shares.
- The filing indicates a passive investment, stating the securities were not acquired and are not held for the purpose of changing or influencing the control of Enanta Pharmaceuticals Inc.
Sentiment
Score: 6
Explanation: The filing reports a significant passive ownership stake by a specialized investment firm, which can be viewed as a neutral to slightly positive signal of institutional interest, without providing operational or financial performance details of the issuer.
Positives
- A significant investment firm, Deep Track Capital, has taken a 5.33% stake in Enanta Pharmaceuticals, potentially signaling confidence in the company's future prospects.
Industry Context
Deep Track Capital specializes in biotechnology investments, suggesting their stake in Enanta Pharmaceuticals aligns with their sector focus. This indicates continued institutional interest in the biotechnology sector, particularly in companies like Enanta Pharmaceuticals.
Stakeholder Impact
- Shareholders: Increased institutional ownership by a specialized investment firm could be perceived as a positive signal, potentially enhancing investor confidence and market perception.
Key Dates
| Date | Description |
|---|---|
| 10/01/2025 | Date for outstanding Common Stock calculation (27,877,923 shares) according to the issuer's Prospectus. |
| 10/02/2025 | Date of event which required the filing of this statement. |
| 10/09/2025 | Date of filing and signatures for the Schedule 13G statement. |
Recommendation
holdThe filing indicates a significant passive stake by Deep Track Capital, a specialized biotech investor. While this signals institutional confidence, the filing does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further fundamental analysis or company updates.
Keywords
Enanta Pharmaceuticals, Deep Track Capital, beneficial ownership, Schedule 13G, institutional investment, biotechnology, common stock, ENA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.